ArticleBMC cancer2025
Application of the PDCA cycle in companion diagnostic PD-L1 SP263 immunohistochemical testing.
Article in BMC cancer, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Food Safety Management in Primary Schools for Ethnic Groups in Northern Thailand: A PDCA-Based Evaluation.International journal of environmental research and public health · 2025Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
Abstract
The aim of this study was to investigate application of the PDCA (Plan-Do-Check-Action) cycle in companion diagnostic PD-L1 SP263 immunohistochemical (IHC) testing. By using scientific quality control methods, the accuracy and consistency of the experimental results were ensured.Methods A total of 279 cases of PD-L1 SP263 IHC testing conducted in our hospital from May 2021 to December 2021 were collected. The PDCA cycle method was applied, and quality control data before and after its implementation were analyzed and compared.Results The application of the PDCA cycle effectively strengthened quality control management that significantly improved the accuracy and consistency of PD-L1 SP263 IHC testing results.Conclusion PD-L1 SP263 testing has value as both a complementary and companion diagnostic test for immunotherapy in malignant tumors, with the accuracy of its results being particularly crucial. The testing process involves pre-analytical, analytical, and post-analytical phases. The application of the PDCA cycle provides a robust scientific approach to aid quality control management throughout the PD-L1 SP263 testing process.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.